Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies and has reached millions of patients globally.
Ascendis Pharma is applying its innovative platform technology to build a leading, fully-integrated biopharma company. Guided by our core values of patients, science and passion, we use our TransCon technology to create new and potentially best in class therapies. We have a pipeline of three independent endocrinology rare disease product candidates in clinical development and are advancing oncology as a second therapeutic area of focus. We continue to expand into additional therapeutic areas to address unmet patient needs. Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.
Bruker-MicroCT develops and manufactures micro and nano-CT scanners both in vivo and ex vivo, with the highest resolution and imaging performance over both categories. Bruker SkyScan scanners have been essential tools for bone researchers for more than 2 decades. In-vivo imaging with physiological monitoring is within proven safe dose limits. Scanners are supplied with comprehensive analysis software featuring high speed GPU reconstruction, versatile volume of interest selection tools including trabecular-cortical separation, calibrated BMD/TMD, comprehensive 3d and 2d parameters (ASBMR-compliant) and customisable batch operations. In-depth bone research and morphometry support is provided. Bruker-MicroCT customers are closely supported by 66 distributors worldwide.
Elsevier journals in the musculoskeletal field provide a stage for global research collaboration. Our journals, broad ranging in scope, serve the research needs of educators, clinicians, researchers and students forging developments and discoveries with significant real-world impacts. Browse our journals and books here: https://www.sciencedirect.com/browse/journals-and-books.
Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalization of EUR 3.8 billion (USD 4.5 billion) by the end of 2020, Richter’s consolidated sales were approximately EUR 1.6 billion (USD 1.8 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women’s Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women’s Healthcare field worldwide. Richter is also active in biosimilar product development.
Hologic’s increased portfolio dedicated to life sciences allows scientists and researchers more timely discoveries and effective was to ensure the integrity of their work. Hologic offers compact digital imaging and pre-clinical systems with the highest resolution (< 10µm) and the largest field of view in the market. Hologic x-ray cabinets can be placed directly in the animal facility or surgical suite with no other shielding required.
International Conference on Children’s Bone Health (ICCBH)
ICCBH is your opportunity to hear about and discuss the newest developments in our understanding of paediatric bone health and disease. The biennial ICCBH conference is attended by over 600 delegates from across the globe, making it truly multinational and multidisciplinary – a unique networking opportunity.
10th International Conference on Children’s Bone Health
2-5 July 2022, Dublin, Ireland
Abstract deadline: 14 February 2022
ICCBH Bone School
29 June to 1 July 2022, Dublin, Ireland
A 3-day educational course on paediatric bone health and rare bone diseases
14th International Conference on Osteogenesis Imperfecta
30 August to 2 September 2022, Sheffield, UK
Abstract deadline: 25 April 2022
ICCBH New Investigator Networking Group
Aims: To keep the community connected and support career development.
Target audience: Early career clinical and basic researchers with focus on paediatric bone health from anywhere in the world.
Next meeting: 14 May 2021 13:00 CET ‘How to prepare and deliver a good talk’ with speaker Leanne Ward.
Info/register by email via the organisers: Adi Raimann and Marie-Eve Robinson at firstname.lastname@example.org.
Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization.
Through our in-depth understanding of the biological pathways involved in mineralization, we are pursuing the development of therapeutics to address the underlying causes of these debilitating diseases.
It is well established that two genes, ENPP1 and ABCC6, play key roles in a critical mineralization pathway and that defects in these genes lead to abnormal mineralization.
We are initially focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.
Ipsen is a leading global biopharmaceutical company focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Active in the rare diseases ﬁeld for many years, Ipsen brings scientiﬁc advancements to patients and invests signiﬁcantly in R&D, leveraging global expertise and a local presence. Ipsen is committed to making innovative new treatments available to people living with rare diseases.
For more information on Ipsen, please visit www.ipsen.com.
Karger Publishers, headquartered in Basel, Switzerland, is a globally active publishing house in Health Sciences. It is independent and family-run in the fourth generation with 240 employees worldwide.
S. Karger AG consists of the publishing company Karger Publishers (est. 1890) and the International Subscription Agency Karger Libri (est. 1960).
Chairwoman and Publisher Gabriella Karger leads the publishing company and S. Karger AG together with CEO Daniel Ebneter and COO Andre Janssen.
There are also subsidiaries in Freiburg, Germany and Abingdon, United Kingdom, there are Karger regional offices or representatives in Australia, China, France, India, Japan, Malaysia, Mexico, the Russian Federation, Thailand, the United Arab Emirates, and the United States.
Scanco Medical AG (www.scanco.ch), established 1988, is a global provider of microCT, VivaCT and XtremeCT (HR-pQCT) systems as well as scan/analysis services. Systems are bundled with sophisticated, easy to use, analysis and visualization software as well as automatic specimen changers (specimen systems only).
Scanco Medical is the only company which offers a fully integrated optional Finite Element Analysis Software package with its systems. Optional hardware include a mechanical testing stage and GPU reconstruction engine.
Scanco Medical is also pleased to announce the availability of complete Windows® based systems beginning 2021. We wish all ECTS participants the best for the future.
The Nestlé Nutrition Institute (NNI), as a non for profit association in Switzerland, shares leading science based information and education with practicing health professionals in all parts of the world.
NNI is committed to foster the highest levels of discussion within scientific community and build nutrition knowledge globally. All NNI exclusive resources are available at http://www.nestlenutrition-institute.org.
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions
to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
With 7 500 people in approximately 40 countries, UCB is continuously working to advance science and embrace new knowledge.
We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology.
Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives.
The European Calcified Tissue Society is a medical society bringing together researchers and clinicians working in the field of calcified tissues and related fields. For over 50 years, ECTS is dedicated to pursuing excellence in research, best practices and in providing education to all those interested in the field. While ECTS is founded in Europe, we engage globally with all stakeholders in the field. Membership is open to anyone working in the field at whatever stage in their career. Come and meet us during ECTS 2021 at our virtual booth.
Visit our website www.ectsoc.org and follow up on twitter @ECTS_soc | @ECTS_science